AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$NAMS

Kastelein Johannes Jacob Pieter sold $3.4M of NAMS (indirect holdings)

Kastelein Johannes Jacob Pieter (Chief Scientific Officer) sold 125,000 indirectly-held shares of NewAmsterdam Pharma Co N.V. (NAMS) at $26.91 ($3.36M total) on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kastelein Johannes Jacob Pieter
Published Aug 25, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NAMS
Bearish
medium confidence
Mentioned
$NAMS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NAMSBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership, which may be interpreted as a lack of confidence, but could also be a pre‑planned liquidity event.

02

Market read

Primary insider sale provides fresh data for traders monitoring biotech equities and insider activity.

03

What to watch

Potential upcoming clinical data releases or partnership announcements that could offset the negative signal.

Relevance 5/10Novelty 7/10Timing: today

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$NAMSBearishMedium confidence
Context

Chief Scientific Officer sold 125,000 shares for $3.36M via a 10b5‑1 plan, reducing his stake to 69,302 shares.

Expected impact

modest short‑term decline

Evidence & confidence

A C‑suite insider disposing of a sizable position via a pre‑arranged plan often leads traders to anticipate selling pressure, though the market may have already priced the disclosure.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company‑specific.

Regional

No regional effect; the filing is a U.S. SEC disclosure.

Global

Limited to investors tracking insider activity in biotech stocks.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals, so the stock may remain stable.

Key entities

  • Company
    NewAmsterdam Pharma Co N.V.

    Biotech firm focused on developing therapies for rare diseases.

  • Individual
    Kastelein Johannes Jacob Pieter

    Chief Scientific Officer of NewAmsterdam Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NAMS insider trading history →

Related articles

AUG 5
$NAMSMed

NewAmsterdam Pharma Co N.V. (NAMS): Results of Operations and Financial Condition

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20

SEC EDGAR 8-K7 min
JUL 24
$NAMSMed

NewAmsterdam, Menarini Cholesterol Drugs Receive Positive Opinion From CHMP

NewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.

rttnews.com3 min
JUL 24
$NAMSMedAI 8/10

Menarini Industrie Farmaceutiche Riunite: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Ob

NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending EU marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing LDL-C reductions up to 40% and about 50%. The European Commission decision is expected in 2H26.

finanznachrichten.de6 min
JUL 24
$NAMSMedAI 8/10

NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapi

NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending marketing authorization in Europe for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM results showing LDL-C reductions up to 40% and about 50%. European Commission decision expected in 2H26.

finanznachrichten.de4 min